When do you plan to add bevacizumab to pembrolizumab/paclitaxel (KEYNOTE-B96) in patients with PD-L1 positive platinum-resistant ovarian cancer?

How often do you add bevacizumab to pembrolizumab/paclitaxel for PD-L1-positive platinum-resistant ovarian cancer?

• Routinely, unless contraindicated
• Only if bevacizumab-naive
• Only for specific indications, such as ascites or effusions
• Only in patients with no bowel involvement or obstruction risk
• Rarely or never
• Other